Merck & Co. won’t move forward with an ultra-short hepatitis C regimen that attempted to cut treatment durations in half by combining two of its drugs with another from Gilead Sciences Inc. (NASDAQ:GILD). Gilead Sciences Inc. (NASDAQ:GILD) belongs to Healthcare sector. Its net profit margin is 45.40% and weekly performance is -4.96%. On last trading day company shares ended up $106.45. Gilead Sciences Inc. (NASDAQ:GILD) … Continue reading Morning Watch List: Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Planar Systems Inc. (NASDAQ:PLNR), Grupo Financiero Santander Mexico (NYSE:BSMX), ULTA